Want to see GB:NFX full AI Analyst Report?
Nuformix Plc (NFX) AI Stock Analysis
Nuformix Plc
(LSE:NFX)
The overall score is driven mainly by very weak financial performance—no revenue, ongoing losses, cash burn, and a shrinking asset base—despite a debt-free balance sheet, while technical indicators show a modestly bearish trend and the valuation remains speculative due to negative earnings and no visible dividend support.
Nuformix Plc (NFX) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 2.74M
- Dividend Yield
- ―
- Average Volume (3M)
- 22.71M
- Price to Earnings (P/E)
- -2.2
- Beta (1Y)
- -0.23
- Revenue Growth
- ―
- EPS Growth
- 93.02%
- Country
- UK
- Employees
- 3
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Nuformix Plc Business Overview & Revenue Model
Company Description
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001...
How the Company Makes Money
Nuformix Plc’s monetization is primarily expected to come from developing its drug candidates and then generating proceeds through commercial partnering rather than large-scale in-house manufacturing and sales. Key revenue streams would typically inc...
Nuformix Plc Financial Statement Overview
Summary
Financial health is weak, with no revenue in recent years, persistent net losses, negative operating cash flow, and shrinking equity and assets, partially offset by a debt-free balance sheet and modest loss and free cash flow improvement.
Income Statement
15Very NegativeBalance Sheet
75PositiveCash Flow
25Negative| Breakdown | TTM | Sep 2025 | Sep 2024 | Mar 2023 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 50.00K | 195.55K |
| Gross Profit | -14.04K | -28.63K | -29.17K | -36.75K | 11.33K | 86.72K |
| EBITDA | -978.41K | -631.94K | -477.19K | -581.90K | -1.23M | -1.28M |
| Net Income | -998.79K | -652.59K | -3.64M | -572.98K | -1.11M | -1.25M |
Balance Sheet | ||||||
| Total Assets | 1.86M | 1.02M | 970.54K | 4.42M | 4.98M | 6.01M |
| Cash, Cash Equivalents and Short-Term Investments | 930.28K | 97.55K | 20.21K | 202.55K | 464.10K | 1.67M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 227.21K | 263.92K | 254.97K | 222.99K | 237.86K | 324.62K |
| Stockholders Equity | 1.64M | 754.93K | 715.57K | 4.20M | 4.74M | 5.69M |
Cash Flow | ||||||
| Free Cash Flow | -618.91K | -614.61K | -331.88K | -397.49K | -1.35M | -848.83K |
| Operating Cash Flow | -618.91K | -614.61K | -331.88K | -397.49K | -1.35M | -848.22K |
| Investing Cash Flow | 0 | 0 | 0 | 33.33K | 0 | 43.72K |
| Financing Cash Flow | 1.45M | 691.95K | 149.54K | 189.79K | 139.98K | 1.93M |
Nuformix Plc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:NFX, the sentiment is Negative. The current price of 0.10 is below the 20-day moving average (MA) of 0.11, below the 50-day MA of 0.14, and below the 200-day MA of 0.18, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 31.54 is Neutral, neither overbought nor oversold. The STOCH value of 23.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:NFX.
Nuformix Plc Peers Comparison
Overall Rating
GB:FUM46Neutral
GB:HEMO46Neutral
GB:IMM42Neutral
GB:TCF42Neutral
GB:OPTI41Neutral- GB:NFX39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:FUM | 46Neutral | GBP 2.59M | -0.28 | -152.41% | ― | -70.77% | 60.39% |
| GB:HEMO | 46Neutral | GBP 39.04M | -3.13 | -409.57% | ― | ― | 18.57% |
| GB:IMM | 42Neutral | GBP 20.28M | -2.60 | -559.87% | ― | ― | 5.62% |
| GB:TCF | 42Neutral | GBP 4.64M | -1.70 | -93.92% | ― | ― | 55.56% |
| GB:OPTI | 41Neutral | GBP 5.99M | -1.40 | -77.85% | ― | 11.90% | -2864.29% |
| GB:NFX | 39Underperform | GBP 2.74M | -2.23 | -83.53% | ― | ― | 93.02% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:NFX | Nuformix Plc | 0.10 | -0.38 | -78.35% | |
| GB:TCF | Evgen Pharma | 0.17 | -0.04 | -19.05% | |
| GB:FUM | Futura Medical | 0.17 | -2.43 | -93.27% | |
| GB:IMM | ImmuPharma plc | 3.25 | -7.15 | -68.75% | |
| GB:OPTI | OptiBiotix Health | 5.80 | -2.20 | -27.50% | |
| GB:HEMO | Hemogenyx Pharmaceuticals Plc | 566.00 | -262.00 | -31.64% |
Nuformix Plc Corporate Events
Nuformix boosts NXP002 case with new TGF-β pathway data
PositiveNuformix has reported further positive preclinical data for NXP002, its lead inhaled therapy candidate for idiopathic pulmonary fibrosis, progressive pulmonary fibrosis and related interstitial lung diseases. The latest pilot inhaled target engagemen...
Nuformix appoints Tim Metcalfe as new chairman to drive strategic value
PositiveNuformix plc has appointed seasoned corporate financier Tim Metcalfe as Non-Executive Chairman and Director, effective 1 September 2026, following the decision of current Chair Julian Gilbert to step down from the board for personal reasons on 31 Aug...
Nuformix Advances Inhaled Fibrosis Drug NXP002 With Positive Preclinical Data
PositiveNuformix has reported positive preclinical data from an inhaled pharmacokinetic and target engagement study of NXP002, its lead inhaled therapy candidate for idiopathic and progressive pulmonary fibrosis and related interstitial lung diseases. The st...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 09, 2026